cholangiocarcinoma
Truseltiq Has FDA Approval Withdrawn for Cholangiocarcinoma
The FDA has announced the final withdrawal of its approval of infigratinib (Truseltiq, QED Therapeutics) for ...
JUNE 24, 2024
Futibatinib Approved for Certain Patients With Advanced Intrahepatic Cholangiocarcinoma
The FDA approved futibatinib (Lytgobi, Taiho Oncology) for the treatment of adult patients with previously ...
OCTOBER 5, 2022
FDA Approves Tibsovo for Adjuvant Treatment of IDH1-Mutated Cholangiocarcinoma
The FDA approved ivosidenib (Tibsovo, Servier) for adults with previously treated, locally advanced or metastatic ...
AUGUST 30, 2021
Early PVT Detection Crucial for Hospitalized Cirrhosis Patients With Liver Cancer
Patients with cirrhosis who also have primary liver cancer face a higher risk for complications and death when they ...
AUGUST 23, 2021
FDA Approves Truseltiq for Some Advanced Cholangiocarcinoma Patients
The FDA granted accelerated approval to infigratinib (Truseltiq, QED Therapeutics) for the treatment of adults with ...
JUNE 4, 2021
Breakthrough Therapy for Advanced Cholangiocarcinoma Approved
The FDA granted accelerated approval to pemigatinib (Pemazyre, Incyte ), the first approved treatment for adults ...
APRIL 22, 2020
